New Features information at Drug Development Technology New and updated information from Features listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Features information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November. Tue, 06 Dec 2016 00:00:00 GMT October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016. Mon, 07 Nov 2016 00:00:00 GMT September's top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada http://www.drugdevelopment-technology.com/features/featureseptembers-top-stories-oncternal-begins-dosing-in-phase-i-trial-of-tk216-phase-ii-trial-of-medical-cannabis-in-canada-begin-5022063/ http://www.drugdevelopment-technology.com/features/featureseptembers-top-stories-oncternal-begins-dosing-in-phase-i-trial-of-tk216-phase-ii-trial-of-medical-cannabis-in-canada-begin-5022063/ Oncternal Therapeutics began dosing patients in its Phase I clinical trial of TK216 to treat Ewing sarcoma and Tilray and University of British Columbia began patient enrolment in Canada’s first Phase II clinical trial of medical cannabis to treat po… Thu, 06 Oct 2016 23:00:00 GMT August's top stories: Gradalis' Phase I breast cancer trial, Biothera and Merck conducted combination cancer immunotherapy trials http://www.drugdevelopment-technology.com/features/featureaugusts-top-stories-gradalis-phase-i-breast-cancer-trial-biothera-and-merck-to-conduct-combination-cancer-immunotherapy-trials-4996151/ http://www.drugdevelopment-technology.com/features/featureaugusts-top-stories-gradalis-phase-i-breast-cancer-trial-biothera-and-merck-to-conduct-combination-cancer-immunotherapy-trials-4996151/ Gradalis dosed the first patient in its pilot Phase I trial of a combination of Vigil Engineered Autologous Tumour Cells (EATCs) and durvalumab to treat advanced breast cancer, and Biothera collaborated with Merck to expand the ongoing clinical progr… Thu, 08 Sep 2016 23:00:00 GMT Pharma Technology Focus – Issue 50 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-50-4988804/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-50-4988804/ In this issue: Maximising investment by cancer megafunds, positive clinical trials for an antibody to treat lupus, how copper can be used to tackle obesity, whether day and night should influence our drug regimes, a device to soak up excess drugs and… Thu, 25 Aug 2016 10:46:00 GMT July's top stories: GBT's Phase II1 trial GBT440, Merck's Phase III trial ONCEMRK of Isentress http://www.drugdevelopment-technology.com/features/featurejulys-top-stories-gbts-phase-ii1-trial-gbt440-mercks-phase-iii-trial-oncemrk-isentress-4972093/ http://www.drugdevelopment-technology.com/features/featurejulys-top-stories-gbts-phase-ii1-trial-gbt440-mercks-phase-iii-trial-oncemrk-isentress-4972093/ Global Blood Therapeutics (GBT) began the Phase IIa trial (GBT440-007) of GBT440 in adolescents with sickle cell disease (SCD), and Merck reported positive results from its ongoing Phase III pivotal trial ONCEMRK of Isentress (raltegravir) to treat a… Mon, 08 Aug 2016 23:00:00 GMT June's top stories: Bayer reported positive results of RESORCE trial, TapImmune initiated Phase II trial of TPIV 200 http://www.drugdevelopment-technology.com/features/featurejune-top-stories-bayers-positive-results-resorce-trial-tapimmunes-phase-ii-trial-tpiv-200-4939249/ http://www.drugdevelopment-technology.com/features/featurejune-top-stories-bayers-positive-results-resorce-trial-tapimmunes-phase-ii-trial-tpiv-200-4939249/ Bayer reported positive results from the Phase III RESORCE trial of Stivarga (regorafenib) tablets to treat unresectable hepatocellular carcinoma, and TapImmune initiated its Phase II trial of cancer vaccine TPIV 200. Drugdevelopment-technology.com w… Tue, 05 Jul 2016 23:00:00 GMT May's top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial http://www.drugdevelopment-technology.com/features/featuremays-top-stories-promedica-begin-human-stem-cell-trial-cerulean-doses-phase-lll-combination-trial-4907578/ http://www.drugdevelopment-technology.com/features/featuremays-top-stories-promedica-begin-human-stem-cell-trial-cerulean-doses-phase-lll-combination-trial-4907578/ ProMedica and Stemedica planned to begin a human stem cell trial for traumatic brain injury and Cerulean dosed its first patient in a Phase l/ll combination trial of CRLX101 and lynparza. Drugdevelopment-technology.com wraps up the key headlines from… Mon, 06 Jun 2016 23:00:00 GMT April's top stories: SynbiCITE's synthetic biology foundry, Omeros's phase II clinical trial of OMS721 http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-synbicites-synthetic-biology-foundry-omeross-phase-ii-clinical-trial-oms721-4876831/ http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-synbicites-synthetic-biology-foundry-omeross-phase-ii-clinical-trial-oms721-4876831/ SynbiCITE opened a commercial synthetic biology foundry at Imperial College London, and Omeros began dosing patients in its new Phase ll clinical trial of OMS721 in corticosteroid-dependent renal diseases. Drugdevelopment-technology.com wraps up the … Wed, 04 May 2016 23:00:00 GMT March's top stories: Tracon's Phase IbTRC105 clinical trial, ADC begins ADCT-402 trial http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-tracons-phase-ib-clinical-trial-of-trc105-adc-begins-adct-402-trial-4851960/ http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-tracons-phase-ib-clinical-trial-of-trc105-adc-begins-adct-402-trial-4851960/ Tracon Pharmaceuticals started Phase Ib clinical trial of TRC105, a clinical stage antibody to endoglin, and ADC Therapeutics began a Phase I trial of its antibody drug conjugate (ADC) ADCT-402. Drugdevelopment-technology.com wraps-up the key headlin… Mon, 04 Apr 2016 23:00:00 GMT Pharma Technology Focus – Issue 45 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-45-4850481/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-45-4850481/ In this issue: Israel’s pharma market, what Brexit would mean for clinical research in the UK, developments in obstetrics, the trouble with inhalable insulin, the FDA’s new support for innovation in manufacturing, plant-based vaccine manufacturing an… Tue, 29 Mar 2016 14:15:00 GMT February's top stories: 60% of trial results not shared, Dilaforette-AGU team-up http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-60-of-clinical-trial-results-not-shared-dilaforette-and-agu-team-up-4830250/ http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-60-of-clinical-trial-results-not-shared-dilaforette-and-agu-team-up-4830250/ Yale School of Medicine researchers revealed about 60% of academic clinical trial results were not shared after completion, and Dilaforette and Arabian Gulf University were to collaborate on a Phase II proof-of-concept trial of sevuparin in patients … Mon, 07 Mar 2016 00:00:00 GMT Pharma Technology Focus - Issue 44 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus---issue-44-4814226/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus---issue-44-4814226/ In this issue: Clinical trials in Russia, how understanding the microbiome could help with drug delivery, making the most of data analytics, the potential of wearable trackers in clinical trial data collection, the pharma industry's role in fighting … Mon, 22 Feb 2016 12:52:00 GMT January's top stories: Profectus Ebola trial, AstraZeneca-Incyte lung cancer drug http://www.drugdevelopment-technology.com/features/featurejanuary-top-stories-2016-drug-4803595/ http://www.drugdevelopment-technology.com/features/featurejanuary-top-stories-2016-drug-4803595/ Profectus BioSciences began VesiculoVax-vectored vaccine trial, AstraZeneca and Incyte announced combination drug evaluation, SillaJen started Phase III trial for Pexa-Vec. Drugdevelopment-technology.com wraps-up the key headlines from January. Fri, 05 Feb 2016 00:00:00 GMT Pharma Technology Focus – Issue 43 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-43-4789326/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-43-4789326/ In this issue: A look inside China’s pharmaceutical market, GSK’s pipeline to 2020, tackling the world’s most pressing clinical needs, new digital tools for clinical trials, a new approach to predicting side effects and more. Thu, 21 Jan 2016 16:45:00 GMT 2015: The year's biggest Drug Development Technology stories http://www.drugdevelopment-technology.com/features/feature2015-the-years-biggest-drug-development-technology-stories-4765177/ http://www.drugdevelopment-technology.com/features/feature2015-the-years-biggest-drug-development-technology-stories-4765177/ UK develops method to improve drug delivery in cancer treatment, skin cancer drug trial starts in UK, and Nestlé and EpiGen to assess impact of nutrients during pregnancy. Drug Development-technology.com wraps up the key headlines from 2015. Tue, 05 Jan 2016 11:22:00 GMT November's top stories: Phase III trial of sirukumab, Lyrica fails trial http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-phase-iii-trial-of-sirukumab-lyrica-fails-trial-4744088/ http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-phase-iii-trial-of-sirukumab-lyrica-fails-trial-4744088/ GlaxoSmithKline begins Phase III trial of sirukumab, Pfizer's neuropathic pain drug Lyrica fails Phase III trial, and Seattle begins Phase I/II trial of SGN-CD33A. Drugdevelopment-technology.com wraps up key headlines from November. Fri, 11 Dec 2015 11:58:00 GMT Pharma Technology Focus – Issue 42 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-42-4749436/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-42-4749436/ In this issue: Bridging the GP - big pharma divide, the year ahead in regulation, world-changing research into parasitic diseases, the first 3D printing method for adult stem cells, the ethics of marketing pharmaceuticals online, and more. Fri, 11 Dec 2015 11:13:00 GMT Pharma Technology Focus - Issue 41 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus---issue-41-4736126/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus---issue-41-4736126/ In this issue: regulation updates for EU-FMD and IDMP, why flibanserin remains controversial, why farm dust could be the key to preventing asthma, new efforts to reduce placebo use in clinical trials, and more. Tue, 24 Nov 2015 14:51:00 GMT October's top stories: New cancer drug delivery approach, J&J Ebola trial http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-new-cancer-drug-delivery-approach-jj-ebola-trial-4712188/ http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-new-cancer-drug-delivery-approach-jj-ebola-trial-4712188/ UK researchers develop a new method to improve drug delivery in cancer treatment, J&J initiates clinical trial of Janssen's Ebola prime-boost vaccine regimen in Sierra Leone and Bayer begins Phase III trial of riociguat to treat children with PAH. Dr… Thu, 05 Nov 2015 00:00:00 GMT